ÂÜÀòÂÒÂ×

Jeremy Myers is vice president of research and development for EvolveImmune Therapeutics. In his current role, Jeremy leads biology and biotherapeutic discovery.

From 2010-2020, Jeremy helped lead Pfizer oncology research and development in Pearl River, NY. Initially, as a director of the Oncology Target Discovery Team, he led cell surface antigen discovery efforts and interrogation of biotherapeutic targets for antibody drug conjugates and T-cell retargeting bispecific antibody therapeutics. In 2017, Jeremy led the Oncology Biotherapeutic Discovery Group including the development of tumor targeted immunotherapies leveraging antibody discovery and rational protein design. From 2018-2020, Jeremy was senior director, head of the Integrative Biotechnology Group, and a member of Pfizer Oncology Research and Development Leadership Team.

Prior to Pfizer, Jeremy was a research faculty member and AstraZeneca Research Fellow in the Department of Biochemistry at Vanderbilt University Medical School. Jeremy received his BSc in biology from Bucknell University. He completed his Ph.D. studies in biochemistry and molecular biology at the LSU Health Sciences Center and Louisiana State University. He completed a postdoctoral fellowship at Vanderbilt University.